

CONSENSUS PERSPECTIVE

Considerations for Endpoints in Lung Transplant Clinical Trials: Perspective on the ISHLT Consensus Statement



John R. Greenland, MD, PhD,^a Michael Perch, MD,^b Kieran Halloran, MD, MSc,^c Deborah J. Levine, MD,^d Eric D. Morrell, MD, MA,^e Anna Reed, MBChB,^f Ciara M. Shaver, MD, PhD,^g Jonathan P. Singer, MD, MS,^a Stuart C. Sweet, MD, PhD,^h Robin Vos, MD, PhD,ⁱ Shambhu Aryal, MD, FCCP,^j Nicholas Avdimiretz, MD, FRCPC,^k Fay Burrows, Bpharm,^l Daniel Calabrese, MD,^a Fiorella Calabrese, MD,^m Silvia Campos, PhD,ⁿ Michael Combs, MD, MS,^o Marc de Perrot, MD, MSc, FRCSC,^p Göran Dellgren, MD, PhD,^q Joshua M. Diamond, MD, MS,^r Thomas Egan, MD, MSc,^s Patricia Ging, MSc,^t David V. Glidden, PhD,^u Martin Goddard, MB BCh, FRCS, FRCPath,^v Soma Jyothula, MD,^w Michael Keller, MD,^x Hrishikesh Kulkarni, MD, MSCI,^y Johanna M. Kwakkel-van Erp, MD, PhD,^z Vibha Lama, MD, MS,^{aa} Nandor Marczin, MD, PhD,^{ab,ac,ad} Tereza Martinu, MD, MHS,^{ae} Megan L. Neely, PhD,^{af} Scott M. Palmer, MD, MHS,^{ag} Caroline M. Patterson, BMBS, MD,^{ah} Elizabeth N. Pavlisko, MD,^{ai} Christine Pham, PharmD,^{aj} Melissa Sanchez, PsyD, MSc,^{ak} Hans Henrik L. Schultz, MD, PhD,^{al} Nicolaus Schwerk, MD, PhD,^{am} Unmil Shah, MD,^{an} Michael Shashaty, MD, MSCE,^r Lianne Singer, MD,^{ao} Patrick Smith, PhD, MPH,^{ap} Laurie D. Snyder, MD, MHS,^{ag} Melinda Solomon, MD, MSc,^{aq} Stijn Verleden, PhD,^{ar} Veronique Verplancke, MD,^{ar} Adriana Zeevi, PhD, ABHI,^{as} and Jamie L. Todd, MD, MHS^{ag}

^aDepartment of Medicine, University of California San Francisco, San Francisco, CA; ^bDepartment of Cardiology, Section for Lung Transplantation, Rigshospitalet, and Department of Clinical Medicine, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark; ^cDepartment of Medicine, University of Alberta, Edmonton, AB, Canada; ^dDepartment of Medicine, Stanford University, Palo Alto, CA; ^eDepartment of Medicine, University of Washington, Seattle, WA; ^fDepartment of Medicine, Harefield Hospital, Uxbridge, UK; ^gDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN; ^hDepartment of Pediatrics, Washington University, Saint Louis, MO; ⁱDepartment of Respiratory Diseases, University Hospitals Leuven and KU Leuven, Leuven, Belgium; ^jDepartment of Advanced Lung Disease and Lung Transplant, Inova Health System, Falls Church, VA; ^kDepartment of Pediatrics, University of British Columbia, BC Children's Hospital, Vancouver, BC, Canada; ^lDepartment of Pharmacy, St. Vincent's Hospital, Sydney, Sydney, Australia; ^mCardiothoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy; ⁿDepartment of Medicine, Heart Institute (InCor) University of Sao Paulo Medical School, Sao Paulo, Brazil; ^oDepartment of Medicine, Vanderbilt University, Nashville, TN; ^pDepartment of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, ON, Canada; ^qCardiothoracic Surgery and Transplant Institute, Sahlgrenska University Hospital and Gothenburg University, Gothenburg, Sweden; ^rDepartment of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA; ^sDepartment of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC; ^tDepartment of Pharmacy, Atlantic Technological University, Sligo, Ireland; ^uDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; ^vDepartment of Pathology, Papworth Hospital, Cambridge, UK; ^wMethodist Heart & Lung Institute, Methodist Hospital, San Antonio, TX; ^xDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD; ^yDepartment of Medicine, University of California Los Angeles, Los Angeles, CA; ^zDepartment of Pulmonology, AZ Voorkempen, Malle, Belgium; ^{aa}Department of Medicine, Emory University, Atlanta, GA; ^{ab}Department of Anaesthesia



To read the full associated guideline, scan the QR code or visit jhltonline.org

DOI of original article: <https://doi.org/10.1016/j.healun.2025.09.017>

Abbreviations: ACR, acute cellular rejection; AMR, antibody-mediated rejection; CLAD, chronic lung allograft dysfunction; ISHLT, International Society for Heart and Lung Transplantation; PFO, physical functioning outcome; PGD, primary graft dysfunction; PRO, patient-reported outcome

Corresponding author: John R Greenland, UCSF Medical Sciences S1057-A, 513 Parnassus Ave, San Francisco, CA 94143, USA.

Corresponding author: Michael Perch, Rigshospitalet, Heartcenter, Inge Lehmanns Vej 7, 2100 Copenhagen, Denmark.

Corresponding author: Jamie L Todd, Duke University MSRB II, Suite 2073, 106 Research Drive, Durham, NC 27710, USA.

E-mail addresses: john.greenland@ucsf.edu, michael.perch@regionh.dk, jamie.todd@duke.edu.

and Intensive Care, Semmelweis University Budapest, Hungary; ^{ac}Department of Anaesthesia, Harefield Hospital, Royal Brompton & Harefield Hospitals, Part of Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; ^{ad}Department of Surgery and Cancer, Imperial College London, London, United Kingdom; ^{ae}Department of Medicine, University of Toronto, Toronto General Hospital, Toronto, ON, Canada; ^{af}Department of Biostatistics and Bioinformatics, Duke University, Durham, NC; ^{ag}Department of Medicine, Duke University, Durham, NC; ^{ah}Department of Medicine, Royal Papworth Hospital, Cambridge, UK; ^{ai}Department of Pathology, Duke University Medical Center, Durham, NC; ^{aj}Department of Pharmacy, St. Joseph's Hospital and Medical Center, Norton Thoracic Institute, Phoenix, AZ; ^{ak}Department of Psychology, Central and North West London NHS Foundation Trust, London, UK; ^{al}Department of Medicine, Copenhagen University Hospital, Copenhagen, Denmark; ^{am}Department of Medicine, Clinic for Pediatric Pneumology, Allergology and Neonatology; Hannover Medical School, Hannover, Germany; ^{an}Department of Pulmonary Medicine, Krishna Institute of Medical Science, Secunderabad, Telangana, India; ^{ao}Department of Medicine, University Health Network, Toronto, Toronto, ON, Canada; ^{ap}Department of Psychiatry and Neurology, University of North Carolina at Chapel Hill, Chapel Hill, NC; ^{aq}Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; ^{ar}Department of Medicine, University of Antwerp, Wilrijk, Belgium; ^{as}Department of Pathology, Surgery, and Immunology, University of Pittsburgh, Pittsburgh, PA.

KEYWORDS:

Lung transplantation; Clinical trial endpoints; Primary graft dysfunction; Chronic lung allograft dysfunction (CLAD); Antibody-mediated rejection (AMR); Patient-reported outcomes (PROs)

1. INTRODUCTION

New therapies are required to enhance survival rates and quality of life following lung transplantation.¹ Developing clinical trials in this field presents with specific challenges due to a limited number of potential participants and the need for extended follow-up periods for certain outcomes. Regulatory agencies evaluate clinical benefit based on changes in how participants feel, function, or survive.² Several shorter-term clinical endpoints are relevant for lung transplant recipients, but there remains uncertainty about their association with clinical benefit. Additionally, best practices for operationalizing and measuring these endpoints within a clinical trial framework, as well as their prioritization, have not been firmly established.

A multidisciplinary working group comprising 49 experts from the International Society for Heart and Lung Transplantation (ISHLT) was convened to develop consensus recommendations on lung transplant clinical trial endpoints beyond mortality. The resulting document is intended as a reference for stakeholders across the lung transplant clinical trial spectrum. It addresses endpoints including primary graft dysfunction (PGD), chronic lung allograft dysfunction (CLAD), acute cellular rejection (ACR), antibody mediated rejection (AMR), complications related to immunosuppression, and patient-reported outcomes (PROs). For each endpoint, the document describes the relationship of the endpoint to mortality or other clinically meaningful longer-term outcomes and gives recommendations on the approach to measure, operationalize, and, if applicable, adjudicate these conditions when used as trial endpoints. Simplified definitions are provided for some endpoints to enable their operationalization within the context of an interventional trial.

The Delphi method was used to facilitate and evaluate consensus around recommendation statements, identifying areas of strong agreement, and illuminating areas of less strong agreement where further research would be helpful to strengthen the evidence base. Below, we highlight some of the questions and areas of uncertainty addressed by the expert recommendations for each lung transplant interventional trial endpoint.

2. KEY TAKEAWAYS

1. The document proposes an optimal grade and timepoint of PGD assessment for a trial endpoint, clarifies PGD grading in participants on extracorporeal life support, and addresses whether central adjudication of radiographs and oxygenation information are required when PGD is used as a trial endpoint. The document also proposes a threshold for absolute or relative change in the rate of severe PGD that may be considered clinically meaningful based on available data and expert opinion.



To read the full associated guideline, scan the QR code or visit jhltonline.org

2. The document provides a strong rationale for using probable CLAD as a primary endpoint. For CLAD treatment trials, consensus is reported on clinically meaningful lung function outcomes, analytic strategies to account for the competing risks of death or retransplant, and the lung function decline parameters needed to optimize the target population. Other important variables to collect and consider, such as baseline lung allograft function and time posttransplant, are discussed and the value of blinded CLAD adjudication is addressed.
3. ACR and AMR are important endpoints. Given challenges seen using variable ACR trial endpoint definitions, the document proposes a robust and operationalizable ACR endpoint, supported by available literature and expert opinion, and endorses practices to standardize ACR pathological interpretation across participating centers. With regard to AMR, it is acknowledged that the definition of AMR as originally reported in the ISHLT 2016 consensus document and revisited in a recent ISHLT working group³ is challenging to operationalize in the clinical trial framework. Thus, the document considers the strength of the evidence supporting AMR as a clinical trial endpoint and proposes a simplified and reproducible approach to define AMR when used as a clinical trial endpoint.
4. Endpoints such as PGD, CLAD, ACR, and AMR do not capture all of what is important to patients. Measuring the impact of investigational therapies on how patients feel and function is important to stakeholders across the clinical trial spectrum including patients, physicians, and regulatory bodies. The document provides a detailed synthesis of patient-reported outcome (PRO) measures and physical function outcome (PFO) measures to guide selection for trials. There are both generic and lung transplant-specific PRO and PFO instruments that meet key validity criteria for use in clinical trials in lung transplantation, but the domains measured, responsiveness to transplant, and time needed to complete vary across the instruments.
5. The document considers points regarding the evaluation of complications of immunosuppression during trial conduct, with detailed guidance on assessment of infection and renal impairment. Additionally, specific considerations relevant to clinical trials in the pediatric lung transplant population are given, including ensuring robust plans to extrapolate data from adult trials to children given declining numbers of pediatric recipients limit trials exclusively in this population.

3. CONCLUSION

This statement provides guidance on endpoints for clinical trials in lung transplantation, describing their relative merit and offering direction on robust measurement. Emerging concepts in the lung transplant field, such as acute lung allograft dysfunction and baseline lung allograft dysfunction,⁴ may be relevant to future lung transplant clinical trials, but were not explored in detail because their definitions and construct validity are still being established. We also acknowledge that various biological measures, such as circulating donor-derived cell-free DNA and transcriptomic or cellular profiling, may have an emerging role in targeting therapies to high-risk individuals or individuals with specific endotypic features,⁵ yet detailed discussion of surrogate biomarker endpoints were beyond the scope of the current document.

There is a substantial unmet need for clinical trials in lung transplantation. Such trials are necessary to establish a strong foundation of evidence for current and future therapies. We trust this document will facilitate and accelerate innovative and effective trials in this critical area and illuminate evidence gaps for future research.

References

1. Swaminathan AC, Todd JL, Palmer SM. Advances in human lung transplantation. *Annu Rev Med* 2021;72:135-49.
2. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016-. Reasonably Likely Surrogate Endpoint. 2017 Sep 25 [Updated 2020 Sep 23].



To read the full associated guideline, scan the QR code or visit jhltonline.org

3. Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. *J Heart Lung Transpl* 2016;35:397-406.
4. Verleden GM, Bos S. The ABC of transplant: ALAD, BLAD, and CLAD: definition and significance. *Curr Opin Pulm Med* 2025.
5. Verleden SE, Hendriks JMH, Lauwers P, Yogeswaran SK, Verplancke V, Kwakkel-Van-Erp JM. Biomarkers for chronic lung allograft dysfunction: ready for prime time? *Transplantation* 2023;107:341-50.



To read the full associated guideline, scan the QR code or visit jhltonline.org